Holland & Barrett International, the UK's leading health and wellness retailer, has launched the first commercially available effervescent product containing Gencor’s Levagen PEA, called Vitaboost Levagen, making it the second Gencor and Pharmako partnered product launched by Holland & Barrett.
Vitaboost Levagen is a specially formulated non-hemp CBD alternative, palmitoylethanolamide (PEA), developed with the dispersion technology Lipisperse, which increases the bioavailability and functionality of the ingredient.
“PEA was first identified in the 1950s as a potent anti-inflammatory and, today, Gencor has extensively studied its safety and efficacy for a variety of health conditions and as a CBD alternative,” said Chase Shryoc, VP of Sales and Business Development at Gencor. “PEA is the next generation of anti-inflammatory analgesics.”
“Although biogenetically different, CBD and PEA share a remarkable series of pharmacological similarities,” said Mariko Hill, Product Development Executive at Gencor.
“Published studies have shown PEA to be effective in joint health, sports recovery and sleep. We are thrilled about the launch of this new product to help consumers receive the benefits of CBD, without consuming the potentially illegal product.”
The use of CBD and NSAIDS are a large issue in the realm of sport, thus Levagen+ provides a safer and more effective alternative for those athletes who are regularly tested for WADA-banned substances.
"By working with numerous elite teams in the UK, we gain practical insights into the use of Levagen+ in recovery, injury and trauma-based protocols," added Hill.
Featured companies
- Companies:
- Holland and Barrett
- Pharmako Biotechnologies Pty Ltd